A clinical-stage biotechnology company focused on developing gene and cell therapies for rare eye diseases and other serious conditions. Its pipeline includes experimental treatments targeting inherited retinal disorders and biologics platforms, with progress tied closely to clinical trial outcomes ...
1 member of Congress has disclosed 2 trades in Ocugen, Inc. (OCGN), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-11-08 | Christopher L. Jacobs | sell | $1K – $15K |
| 2022-06-16 | Christopher L. Jacobs | buy | $15K – $50K |